Autopsy report · NCT00206063
Long Term Open Follow-up With H376/95 vs. Warfarin
Cause of deathFunding or business, also safety
“Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.”
Life of this trial
- Registered 6 years 1 month after it had already started.
- Ran for about 6 years 8 months before it stopped.
- 220 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Stroke Prevention in Patients With Atrial Fibrillation
- Interventions
- EXANTA
- Participants
- 220
- Sites
- 19
- Countries
- Belgium, Czechia, Denmark, Finland, Norway, Poland, Sweden, United Kingdom, United States
Trials that died the same way
- Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A
“The clinical trial was withdrawn due to a commercial decision.” - MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
“Product withdrawn from clinical development” - 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
“Pharmaceutical Company withdrew support and investigational product” - Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
“drug withdrawn from market” - A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
“The study was withdrawn based on business-related matters and there are no new safety concerns related to the trial. No patients were enrolled.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.